These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 35774916)

  • 21. Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review.
    Laguado SA; Saklad SR
    Ment Health Clin; 2022 Aug; 12(4):254-262. PubMed ID: 36071739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.
    Potkin SG; Kunovac J; Silverman BL; Simmons A; Jiang Y; DiPetrillo L; McDonnell D
    J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32141723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin and glucose metabolism with olanzapine and a combination of olanzapine and samidorphan: exploratory phase 1 results in healthy volunteers.
    Toledo FGS; Martin WF; Morrow L; Beysen C; Bajorunas D; Jiang Y; Silverman BL; McDonnell D; Namchuk MN; Newcomer JW; Graham C
    Neuropsychopharmacology; 2022 Feb; 47(3):696-703. PubMed ID: 34887529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers.
    Silverman BL; Martin W; Memisoglu A; DiPetrillo L; Correll CU; Kane JM
    Schizophr Res; 2018 May; 195():245-251. PubMed ID: 29158012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
    Martin WF; Correll CU; Weiden PJ; Jiang Y; Pathak S; DiPetrillo L; Silverman BL; Ehrich EW
    Am J Psychiatry; 2019 Jun; 176(6):457-467. PubMed ID: 30845818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment.
    Grywińska WB; Głowacka A
    Postep Psychiatr Neurol; 2023 Sep; 32(3):128-137. PubMed ID: 38034507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination.
    Sun L; von Moltke L; Rowland Yeo K
    Clin Pharmacokinet; 2021 May; 60(5):637-647. PubMed ID: 33313995
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Precipitated opioid withdrawal in a patient started on olanzapine/samidorphan.
    Chambers A; Patton J; Wills BK
    Am J Emerg Med; 2024 May; 79():230.e1-230.e2. PubMed ID: 38556414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olanzapine/samidorphan (Lybalvi) for schizophrenia and bipolar disorder.
    Med Lett Drugs Ther; 2021 Nov; 63(1638):191-192. PubMed ID: 35085217
    [No Abstract]   [Full Text] [Related]  

  • 31. Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet.
    Sun L; Barter Z; von Moltke L; Rowland Yeo K
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1071-1080. PubMed ID: 34185436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olanzapine/Samidorphan: First Approval.
    Paik J
    Drugs; 2021 Aug; 81(12):1431-1436. PubMed ID: 34304374
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study.
    Citrome L; O'Malley SS; McDonnell D; Jiang Y; Simmons AC; Berry MP; Dipetrillo LE
    Innov Clin Neurosci; 2019 May; 16(5-6):15-21. PubMed ID: 31440397
    [No Abstract]   [Full Text] [Related]  

  • 34. Olanzapine-Samidorphan for Schizophrenia: A Systematic Review and Meta-Analysis.
    Gupta D; Singh A
    Indian J Psychol Med; 2024 Jan; 46(1):14-23. PubMed ID: 38524957
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population Pharmacokinetics of Olanzapine and Samidorphan When Administered in Combination in Healthy Subjects and Patients With Schizophrenia.
    Sun L; Mills R; Sadler BM; Rege B
    J Clin Pharmacol; 2021 Nov; 61(11):1430-1441. PubMed ID: 34018607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial.
    Brunette MF; Correll CU; O'Malley SS; McDonnell D; DiPetrillo L; Jiang Y; Simmons A; Silverman BL; Citrome L; Green AI
    J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32160422
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Olanzapine approved for the acute treatment of schizophrenia or manic/mixed episodes associated with bipolar I disorder in adolescent patients.
    Maloney AE; Sikich L
    Neuropsychiatr Dis Treat; 2010 Nov; 6():749-66. PubMed ID: 21127693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bioequivalence of Olanzapine Given in Combination With Samidorphan as a Bilayer Tablet (ALKS 3831) Compared With Olanzapine-Alone Tablets: Results From a Randomized, Crossover Relative Bioavailability Study.
    Sun L; McDonnell D; Liu J; von Moltke L
    Clin Pharmacol Drug Dev; 2019 May; 8(4):459-466. PubMed ID: 30059196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia.
    Sun L; McDonnell D; von Moltke L
    Clin Ther; 2018 Nov; 40(11):1845-1854.e2. PubMed ID: 30348514
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.